BR0308911A - Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto - Google Patents

Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto

Info

Publication number
BR0308911A
BR0308911A BR0308911-8A BR0308911A BR0308911A BR 0308911 A BR0308911 A BR 0308911A BR 0308911 A BR0308911 A BR 0308911A BR 0308911 A BR0308911 A BR 0308911A
Authority
BR
Brazil
Prior art keywords
compound
pain
pharmaceutical composition
treatment methods
migraine treatment
Prior art date
Application number
BR0308911-8A
Other languages
English (en)
Portuguese (pt)
Inventor
Paul Leslie Ornstein
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0308911A publication Critical patent/BR0308911A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR0308911-8A 2002-04-26 2003-04-14 Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto BR0308911A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37612002P 2002-04-26 2002-04-26
PCT/US2003/010466 WO2003091243A1 (en) 2002-04-26 2003-04-14 Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics

Publications (1)

Publication Number Publication Date
BR0308911A true BR0308911A (pt) 2005-01-04

Family

ID=29270765

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0308911-8A BR0308911A (pt) 2002-04-26 2003-04-14 Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto

Country Status (18)

Country Link
US (1) US7247644B2 (https=)
EP (1) EP1511741B1 (https=)
JP (2) JP2005529892A (https=)
KR (1) KR100757787B1 (https=)
CN (1) CN100436446C (https=)
AU (1) AU2003226277B2 (https=)
BR (1) BR0308911A (https=)
CA (1) CA2480026C (https=)
DK (1) DK1511741T3 (https=)
EA (1) EA009526B1 (https=)
ES (1) ES2398225T3 (https=)
IL (1) IL164773A (https=)
MX (1) MXPA04009857A (https=)
NZ (1) NZ535245A (https=)
PT (1) PT1511741E (https=)
SI (1) SI1511741T1 (https=)
WO (1) WO2003091243A1 (https=)
ZA (1) ZA200409552B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100757787B1 (ko) * 2002-04-26 2007-09-11 일라이 릴리 앤드 캄파니 진통제로서의 데카히드로이소퀴놀린-3-카르복실산의 에스테르 유도체
US8603980B2 (en) 2007-01-16 2013-12-10 The Johns Hopkins University Glutamate receptor antagonists and methods of use
MX2022016223A (es) 2020-07-02 2023-02-23 Sea Pharmaceuticals Llc Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo.
WO2022261287A1 (en) * 2021-06-09 2022-12-15 Proniras Corporation Methods of treating nerve agent-induced seizures
WO2023130008A2 (en) * 2022-01-01 2023-07-06 Sea Pharmaceuticals Llc Pharmaceutical compositions of 6-(2-(2h-tetrazol-5-yl)ethyl)decahydroisoquinoline-3-carboxylic acid and derivatives thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK406686D0 (da) * 1986-08-26 1986-08-26 Hans Bundgaard Carboxylsyrederivater
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5356902A (en) 1992-11-06 1994-10-18 Eli Lilly And Company Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
US5767117A (en) 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
HUP0002030A3 (en) 1997-04-07 2002-01-28 Lilly Co Eli Use of glur5 receptorantagonists for the treatment of pain
EP1200073B1 (en) 1999-07-06 2007-01-10 Eli Lilly And Company SELECTIVE iGluR 5? RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2001002367A2 (en) * 1999-07-06 2001-01-11 Eli Lilly And Company Diester prodrugs of a decahydroisoquinoline-3-carboxylic acid
AU2574801A (en) 1999-12-22 2001-07-03 Eli Lilly And Company Selective iGLUR5 receptor antagonists
WO2002053556A2 (en) 2001-01-05 2002-07-11 Eli Lilly And Company Pyrrolidinylmethyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
WO2003024453A1 (en) 2001-01-05 2003-03-27 Eli Lilly And Company Excitatory amino acid receptor antagonists
AU2002227020A1 (en) 2001-01-05 2002-07-16 Eli Lilly And Company Pyrrolidinylmethyl- and piperidinyl substituted decahydroisoquinolines as excitatory amino acid receptor antagonists
WO2003024934A2 (en) 2001-01-05 2003-03-27 Eli Lilly And Company Derivatives of the (3s, 4ar, 6s, 8ar) 6-phenylamino-1, 2, 3, 4, 4a, 5, 6, 7, 8, 8a-decahydro isoquinoline-3-carboxylic acid as excitatory amino acid receptor antagonists for the treatment of neurological disorders and neurodegenerative diseases
WO2003082856A1 (en) 2002-03-22 2003-10-09 Eli Lilly And Company Isoquinoline-3-carboxylic acid derivatives as excitatory amino acid receptor antagonists
KR100757787B1 (ko) * 2002-04-26 2007-09-11 일라이 릴리 앤드 캄파니 진통제로서의 데카히드로이소퀴놀린-3-카르복실산의 에스테르 유도체

Also Published As

Publication number Publication date
WO2003091243A8 (en) 2005-03-31
CN1649862A (zh) 2005-08-03
ZA200409552B (en) 2006-02-22
IL164773A (en) 2011-08-31
NZ535245A (en) 2007-11-30
PT1511741E (pt) 2013-02-05
JP2010235623A (ja) 2010-10-21
AU2003226277A1 (en) 2003-11-10
IL164773A0 (en) 2005-12-18
DK1511741T3 (da) 2013-01-21
KR20040102171A (ko) 2004-12-03
EA009526B1 (ru) 2008-02-28
CA2480026A1 (en) 2003-11-06
SI1511741T1 (sl) 2013-02-28
CA2480026C (en) 2011-06-07
WO2003091243A1 (en) 2003-11-06
US7247644B2 (en) 2007-07-24
KR100757787B1 (ko) 2007-09-11
EP1511741B1 (en) 2012-12-26
MXPA04009857A (es) 2004-12-07
AU2003226277B2 (en) 2009-03-26
US20050256155A1 (en) 2005-11-17
EP1511741A1 (en) 2005-03-09
JP2005529892A (ja) 2005-10-06
CN100436446C (zh) 2008-11-26
ES2398225T3 (es) 2013-03-14
EA200401432A1 (ru) 2005-04-28

Similar Documents

Publication Publication Date Title
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
BR0315167A (pt) Métodos para tratar a da dor administrando-se um antagonista do fator de crescimento de nervos e um analgésico opióide e composições contendo os mesmos
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
BR9914638A (pt) Composto, método para a preparação do mesmo, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio ou doença de um corpo de animal vivo
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
GB0318447D0 (en) Therapeutic agents
BRPI0417101A (pt) uso de compostos de peptìdeo para tratamento de dor neuropática central
BRPI0410170A (pt) preparação e uso de derivados de ácido aril alquìlico para o tratamento de obesidade
BRPI0412763A (pt) formas anidras, hidratadas ou solvatadas de um composto, forma cristalina, composição farmacêutica, e, método para o tratamento ou a profilaxia de distúrbios
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0007487B8 (pt) difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
ATE496048T1 (de) Phenylcarboxamidverbindungen zur schmerzbehandlung
BR0309486A (pt) Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
BR0111892A (pt) Bis-arilsulfonas
BR0113590A (pt) 7-oxo-piridopirimidinas
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.

B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI